Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

CAR-T therapy safety check: researchers track Long-Term effects in 178 patients

NCT ID NCT07474051

First seen Mar 22, 2026 · Last updated Jun 18, 2026 · Updated 11 times

Summary

This study follows about 178 people who previously received AvenCell's CAR-T cell therapy for blood cancers or prostate cancer. The goal is to monitor long-term safety, including delayed side effects like new cancers or autoimmune problems. Participants are not receiving new treatment but are being observed to better understand the therapy's lasting effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Klinikum der Universität (LMU) Muenchen

    Munich, Germany

  • Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitatsklinikum Ulm

    Ulm, Germany

  • Universitätsklinikum Marburg

    Marburg, Germany

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.